Functional C3435T polymorphism of MDR1 gene: An impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia

European Journal of Haematology

Volumn 72, Issue 5, 2004, Pages 314-321

  Jamroziak, Krzysztof ^a   Młynarski, Wojciech ^a   Balcerczak, Ewa ^a   Mistygacz, Magda ^a   Treliǹska, Joanna ^a   Mirowski, Marek ^a   Bodalski, Jerzy ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute lymphoblastic leukemia; C3435T polymorphism; MDR1; P glycoprotein

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CAUCASIAN; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; EVALUATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEALTH STATUS; HOMOZYGOSITY; HUMAN; MALE; NONBIOLOGICAL MODEL; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ALLELES; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, MDR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIFE TABLES; MALE; MUTATION, MISSENSE; POINT MUTATION; POLAND; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK;

EID: 1942532906     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00228.x     Document Type: Article

References (40)

1. PUI C-H, EVANS WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-615.
2. KRAJINOVIC M, LABUDA D, RICHER C, KARIMI S, SINNETT D. Susceptibility to childhood lymphoblastic leukemia: influence of CYP1a1, CYP2D6, GSTM1 and GSTT1 genetic polymorphisms. Blood 1999;93:1496-1501.
3. MCLEOD HL, KRYNETSKI EY, RELLING MV, EVANS WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukaemia. Leukemia 2000;14:567-572.
4. LAVEDRIERE C, CHIASSON S, COSTEA I, MOGHRABI A, KRAJINOVIC M. Polymorphisms G80A in in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood lymphoblastic leukaemia. Blood 2002;100:3832-3834.
5. JULIANO RL, LING V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162.
6. PENNY JI, CAMPBELL FC. Active transport of benzo[a]pyrene in apical membrane vesicles from normal human intestinal epithelium. Biochim Biophys Acta 1994; 1226:232-236.
7. WALLE KU, WALLE T. Transport of the cook-food mutagen 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) across the human intestinal Caco-2 cell monolayer: role of efflux pumps. Carcinogenesis 1999;20:2153-2157.
8. ILLMER T, SHULER US, THIEDE C, SCHWARZ UI, KIM RB, GOTHARD S, FREUND D, SCHAKEL U, EHNINGER G, SHAICH M. MDR gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62:4955-4962.
9. TAFURI A, GREGORJ C, PETRUCCI MT et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002;100:974-981.
10. AMBDUKAR SV, DEY S, HRYCYNA CA, RAMACHANDRA M, PASTAN I, GOTTESMAN MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-398.
11. SCHINKEL AH, WAGENAAR E, VAN DEEMTER L, MOL CA, BORST P. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-1705.
12. HOFFMEYER S, BURK O, VON RICHTER O et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478.
13. ITO S, IEIRI I, TANABE M, SUZUKI A, HIGUCHI S, OTSUBO K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT in healthy Japanese subjects. Pharmacogenetics 2001;11:175-184.
14. KIM RB, LEAKE BF, CHOO EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199.
15. HITZL M, DRESCHER S, VAN DER KUIP H, SCHAFFELER E, FISCHER J, SCHWAB M, EICHELBAUM M, FROMM MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-298.
16. SIEGSMUND M, BRINKMANN U, SCHAFFELER E et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13:1847-1854.
17. TANABE M, IEIRI I, NAGATA N et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-1143.
18. DRESHER S, SCHAEFFELER, HITZL M, HOFMANN U, SHWAB M, BRINKMAN U, EICHELBAUM M, FROMM MF. MDR1 gene polymorphism and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.
19. FELLAY J, MARZOLINI C, MEADEN ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-36.
20. NAKAMURA T, SAKAEDA T, HORINOUCHI M, TAMURA T, AOYAMA N, SHIRAKAWA T, MATSUO M, KASUGA M, OKUMURA K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71:297-303.
21. SAKAEDA T, NAKAMURA T, HORINOUCHI M et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharmacol Res 2001;18:1400-1404.
22. SIEGMUND W, LUDWIG K, GIESSMANN T, DAZERT P, SCHROEDER E, SPERKER B, WARZOK R, KROEMER HK, CASCORBI I. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002;72:572-583.
23. VON AHSEN N, RICHTER M, GRUPP C, RINGE B, OELLERICH M, ARMSTRONG VW. No influence of MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V Allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001;47:1048-1052.
24. ZHENG H, WEBBER S, ZEEVI A, SCHUETZ E, ZHANG J, LAMBA J, BOWMAN P, BURCKART GJ. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in paediatric heart transplant patients. Hum Immunol 2002;63:765-770.
25. GOTO M, MASUDA S, SAITO H, UEMOTO S, KIUCHI T, TANAKA K, INUI K. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than P-gp in recipients of living-donor liver transplantation. Pharmacogenetics 2002;12:451-454.
26. SCHRAPPE M, REITER A, ZIMMERMANN M, HARBOTT J, LUDWIG WD, HENZE G, GADNER H, ODENWALD E, RIEHM H. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14: 2205-2222.
27. STEINHERZ PG, GAYNON P, MILLER DR, REAMAN G, BLEYER A, FINKLESTEIN J, EVANS RG, MEYERS P, STEINHERZ LJ, SATHER H. Improved disease free survival with children with acute lymhoblastic leukaemia at high risk for early relapse with the New York regimen - a new intensive therapy protocol: a report from the Children Cancer Study Group. J Clin Oncol 1986;4:744-752.
28. JAMROZIAK K, BALCERCZAK E, MłYNARSKI W, MIROWSKI M, ROBAK T. Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol 2002;54:495-500.
29. URAYAMA KY, WIENCKE JK, BUFFLER PL, WIEMELS JL. The role of MDR1 gene polymorphisms in the genetic susceptibility to childhood leukemia. Ann Epidemiol 2002;12:497.
30. POTOCNIK U, RAVNIK-GLAVAC M, GLAVAC D. Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4 mutations in colorectal tumors with high microsatellite instability. Cell Mol Biol Lett 2002;7:92-95.
31. BHATHIA S, SATHER HN, HEEREMA NA, TRIGG ME, GAYNON PS, ROBINSON LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 2002;100:1957-1964.
32. WALTERS TR, BUSHORE M, SIMONE J. Poor prognosis in Negro children with acute lymphoblastic leukaemia. Cancer 1972;29:210-214.
33. SCHAEFFELER E, EICHELBAUM M, BRINKMANN U, PENGER A, ASANTE-POKU S, ZANGER UM, SCHWAB M. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001;358:383-384.
34. CALADO RT, FALCAO RP, GARCIA AB, GABELLINI SM, ZAGO MA, FRANCO RF. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34 + hematopoietic stem cells. Haematologica 2002;87:564-568.
35. STANULLA M, SCHAEFFELER E, SCHRAPPE M, RATHMANN A, ARENS S, WELTE K, EICHELBAUM M, ZANGER U, SCHWAB M. An association between the MDR1 C3435T polymorphism and CNS relapse in childhood acute lymphoblastic leukemia. Blood 2001;98:317a.
36. STEINHERZ PG, GAYNON PS, BRENEMAN JC et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998; 82:600-612.
37. GOLLAPUD S, GUPTA S. Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 2001;21:420-430.
38. DEN BOER ML, PIETERS R, KAZEMIER KM et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998;91:2092-2098.
39. KANERVA J, TIIRIKAINEN MI, MAKIPERNAA A, RIIKONEN P, MOTTONEN M, SALMI TT, KRUSIUS T, SAARINEN-PIKHALA UM. Initial P-glycoprotein expression in childhood lymphoblastic leukaemia: no evidence of prognostic impact in follow-up. Pediatric Hematol Oncol 2001; 18: 27-36.
40. DRACH J, GSUR A, HAMILTON G et al. Involvement of P-gp in the transmembrane transport of Interleukin-2, IL-4 and interferone gamma in normal human T-lymphocytes. Blood 1996;88:1747-1754.